4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (November 2020)
34 slides from 4dmedical's shareholder meeting presentation, Nov 20, 2020
Slide 1: 2020 Annual General Meeting
2020 Annual General Meeting 20 November 2020 ASX: 4DX 4DMedical Limited | ACN 161 684 831
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This Future performance presentation contains summary information about the Company, its subsidiaries and the entities, businesses and This presentation contains certain
Slide 3: 2020 Annual General Meeting
2020 Annual General Meeting Charlene Stahr, Company Secretary 3 | 4DMedical 2020 AGM
Slide 4: 2020 Annual General Meeting – Chairman
2020 Annual General Meeting Bruce Rathie, Chairman 4 | 4DMedical 2020 AGM
Slide 5: 2020 AGM agenda
2020 AGM agenda i. Opening and introductions ii. Procedural matters iii. Chairman’s address iv. Managing Director & CEO’s presentation v. Formal business vi. Closing remarks 5 | 4DMedical 2020 AGM
Slide 6: 4DMedical Board of Directors and Company Secretary
4DMedical Board of Directors and Company Secretary Bruce Rathie Andreas Fouras PhD Lilian Bianchi Dr Robert A. Figlin Chairman, Non- Group Managing Non-Executive Director Non-Executive Director Executive Director Director & Chief (Independent) (Independent) (Independent) Executive Officer Chair, Aud
Slide 7: Procedural Matters
Procedural Matters Charlene Stahr, Company Secretary 7 | 4DMedical 2020 AGM
Slide 8: Procedural matters – how to vote
Procedural matters – how to vote 1. 2. 3. 4. Click “Get a Voting Enter your Shareholder Fill out your voting Click “Submit Card” (top and Number (SRN) or Proxy card for each item Vote” or “Submit bottom of platform) Number and click “Submit of business Partial Vote” Details and Vote” 8 | 4DMedical 2
Slide 9: Procedural matters – how to ask a question
Procedural matters – how to ask a question 1. 2. 3. Click “Ask a Question” Select the item of business from the Once you have typed your (top and bottom of the drop-down menu and type your question, click “Submit platform) question in the space provided. Question” 9 | 4DMedical 2020 AGM
Slide 10: Chairman's Address
Chairman’s Address Bruce Rathie, Chairman 10 | 4DMedical 2020 AGM
Slide 11: FY20 financial dashboard
FY20 financial dashboard Sales revenue Other income Operating costs FY20: $1.23m FY20: $2.14m FY20: $16.07m FY19: $0.70m FY19: $0.86m FY19: $7.08m Up 77% Up 149% Up 127% Sale of preclinical hardware scanners and SaaS Comprises R&D tax incentive credits of $0.82m Driven by increased headcount, clinic
Slide 12: Managing Director & CEO's Presentation
Managing Director & CEO’s Presentation Andreas Fouras, Group Managing Director & CEO 12 | 4DMedical 2020 AGM
Slide 13: Introduction to 4DMedical
Introduction to 4DMedical 13 | 4DMedical 2020 AGM
Slide 14: Global lung diagnostics market opportunity
Global lung diagnostics market opportunity 4DMedical considers its market opportunity to be supplementing or replacing existing respiratory diagnostic modalities. In 2019, more than US$31 billion was spent on respiratory diagnostics across more than 377 million procedures globally. Country Spend (US
Slide 15: The current modality gap
The current modality gap Current best practice respiratory diagnostics are decades out of date, not fit for purpose and are ripe for displacement. While each provides important insights, they often detect lung disease too late for effective treatment. Their limitations leave both doctors and patient
Slide 16: XV Technology combines the best features of existing modalities
XV Technology combines the best features of existing modalities 1) Functional insight of spirometry at a regional level; 2) comparable radiation dose to X-ray; and 3) high-detail resolution of a CT scan Healthy Lung Diseased Lung Subtle defect Uniform ventilation Compensation Defect 16 | 4DMedical 2
Slide 17: FY20 summary & COVID-19 impact
FY20 summary & COVID-19 impact Our main objective in FY20 was FDA 510(k) Our sales and marketing team adapted clearance for our XV LVAS product, which we communication channels to be online, including received in May 2020 virtual trade shows and conferences With over 50 million COVID-19 cases confir
Slide 18: FY20 achievements
FY20 achievements ✓ Jul 2019: Commissioned preclinical scanner at National Imaging Facility, Adelaide ✓ Sep 2019: Fully automated Software-as-a-Service (SaaS) platform, reviewed and verified by clinical expert panel ✓ Oct 2019: Concluded first clinical trial in the U.S. successfully validating the a
Slide 19: Clinical trial pipeline
Clinical trial pipeline 4DMedical currently has over 12 clinical trials in its pipeline at various stages of development 4DMedical has partnered with globally leading hospitals and clinics in pulmonary medicine to address the most complex, prevalent and costly lung conditions. 4DMedical will seek to
Slide 20: FY21 outlook
FY21 outlook With FDA 510(k) clearance and TGA approval, 4DMedical’s focus over the next twelve months will be to: • Accelerate rollout of XV LVAS to priority hospitals in the U.S. and Australia • Continue recruitment of sales and marketing staff in the U.S. and Australia to accelerate revenue gener
Slide 21: Corporate snapshot
Corporate snapshot Capital structure Senior management team Ticker 4DX Andreas Fouras Group Managing Director & CEO IPO offer price $0.73 Heath Lee Chief Financial Officer Share price (18 November 2020) $2.16 Paul Cooke SVP, Sales & Marketing Shares on issue (m) 264.76 Aidan Jamison SVP, Engineering
Slide 22: Formal Business
Formal Business 22 | 4DMedical 2020 AGM
Slide 23: Item 1: Annual Reports
Item 1 Annual Reports To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2020.’ There is no vote on this it
Slide 24: Item 2: Adoption of FY20 Remuneration Report
Item 2 Adoption of FY20 Remuneration Report To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2020, is adopted. Note: under sections 250R(2) and (3) of the Corporations Ac
Slide 25: Item 2: Adoption of FY20 Remuneration Report – votes
Item 2 Adoption of FY20 Remuneration Report To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2020, is adopted. Note: under sections 250R(2) and (3) of the Corporations Ac
Slide 26: Item 3: Re-election of Board endorsed Directors
Item 3 Re-election of Board endorsed Directors Mr Bruce Rathie Ms Lilian Bianchi Non-Executive Director Non-Executive Director (Independent) (Independent) 26 | 4DMedical 2020 AGM
Slide 27: Item 3(a): Re-election of Mr Bruce Rathie
Item 3(a) Re-election of Mr Bruce Rathie Joined board: 11 December 2019 Special responsibilities: Chairman of the Board Background: Bruce is a professional non-executive director of nearly 20 years standing having completed successful prior careers in law and finance. He holds degrees in law (LLB),
Slide 28: Item 3(a): Re-election of Mr Bruce Rathie – votes
Item 3(a) Re-election of Mr Bruce Rathie To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.5, and for all other purposes, Mr Bruce Rathie, a non-executive director appointed on
Slide 29: Item 3(b): Re-election of Ms Lilian Bianchi
Item 3(b) Re-election of Ms Lilian Bianchi Joined board: 11 December 2019 Special responsibilities: Chair of the Audit and Risk Committee Background: Lilian brings invaluable experience in technology products and business transformations, helping lead boards to build an agile and robust strategy thr
Slide 30: Item 3(b): Re-election of Ms Lilian Bianchi – votes
Item 3(b) Re-election of Ms Lilian Bianchi To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.5, and for all other purposes, Ms Lilian Bianchi, a non-executive director appointed
Slide 31: Item 4: Approval of Long Term Incentive Plan
Item 4 Approval in respect of the 4DMedical Long Term Incentive Plan (Incentive Plan) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 7.2 Exception 13 and for all other purposes, the rules of the Incentive Plan (which are
Slide 32: Item 4: Long Term Incentive Plan – votes
Item 4 Approval in respect of the 4DMedical Long Term Incentive Plan (Incentive Plan) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 7.2 Exception 13 and for all other purposes, the rules of the Incentive Plan (which are
Slide 33: Thank you
Thank you 33 | 4DMedical 2020 AGM
Slide 34: 34 | 4DMedical 2020 AGM
34 | 4DMedical 2020 AGM